Tenaya Therapeutics, Inc. Payments of Stock Issuance Costs
Tenaya Therapeutics, Inc. (TNYA) reported Payments of Stock Issuance Costs of $415.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-05
- Tenaya Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00.
- Tenaya Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $415.00K.
- Tenaya Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-06-30 was $0.00.
- Tenaya Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-03-31 was $0.00.
- Tenaya Therapeutics, Inc. payments of stock issuance costs for fiscal 2023 was $501.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $415.00K 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $415.00K 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $0.00 derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $0.00 derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $501.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $501.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $501.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $501.00K 10-Q · filed 2024-05-14 | |||
| 2021-06-30 | $1.39M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |